Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Streptococcus salivarius K12 is an oral probiotic strain isolated from the saliva of a healthy New Zealand child in 1989. It produces two lantibiotics (salivaricin A2 and salivaricin B) that antagonize the growth of Streptococcus pyogenes and other bacterial pathogens. The probiotic is used to prevent recurrent streptococcal and viral infections, reduce oral mucositis, inhibit volatile sulfur compounds associated with halitosis, and improve oral health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Streptococcus salivarius K12.